The ProVent Study
Nearly 175,000 men are diagnosed with prostate cancer every year. Of these, about 30 to 40% with a lower risk of prostate cancer will opt for AS. A new study will evaluate the effectiveness of sipuleucel-T in reducing disease progression in men who are candidates for AS and looking for a proactive alternative to surgery or radiation.
ERA 223 Study
A clinicial research study for patients with asymptomatica/mildly symptomatic castration resistant prostate cancer and two or more bone metastases. Bayer HealthCare is seeking men to participate in a research study of radium-223. The purpose of the ERA 223 trial is to determine if the addition of radium-223 to abiraterone acetate is able to prolong life and to delay events specific for prostate cancer which has spread to the bone, such as bone fractures or bone pain which needs to be treated with an X-Ray machine. This study is enrolling pateints with prostate cancer who, despite medical or surgical castration, have rising prostate specific antigen (PSA) levels. Eligible patients must have two or more bone metastases with no visceral, e.g. liver metastases and not have received prior chemotherapy. Prostate cancer lesions must be asymptomatic or mildly symptomatic. All patients will receive abiraterone acetate along with either radium-223 or placebo.
The MAGNITUDE Study is a Phase 3 randomized, placebocontrolled, doubleblind study comparing a combination of an investigational medicine and standard treatment, to a combination of a placebo and standard treatment for men with metastatic prostate cancer.
The GALAHAD Study
A clinical research study is now enrolling men who have metastatic castration‐resistant prostate
cancer and DNA‐repair anomalies. Janssen Research & Development is seeking men in the US to
participate in a clinical trial of an oral investigational medication for prostate cancer. All participants
will receive daily investigational medication.
To learn more about the Galahad study and find out if you may be eligible, please visit: www.clinicaltrials.gov
Study Identifier: NCT02854436
Janssen Research & Development, LLC is part of the Janssen Pharmaceutical Companies of Johnson & Johnson.